Regenxbio Inc reports results for the quarter ended in September 30 - Earnings Summary

Regenxbio

07/11/2024 04:26

* Regenxbio Inc  RGNX.OQ  reported a quarterly adjusted loss
of
$1.17​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-1.41.  The mean expectation of eleven analysts for the
quarter was for a loss of $1.12 per share. Wall Street expected
results to range from $-1.28 to $-1.05 per share.
    * Revenue fell 16.3% to $24.20 million from a year ago;
analysts
expected $23.59 million. 
    * Regenxbio Inc's reported EPS for the quarter was a loss of
$1.17​.
    * The company reported a quarterly loss of $59.6 million.
    * Regenxbio Inc shares had fallen by 15.0% this quarter and
lost 50.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Regenxbio Inc is
$39.00 
This summary was machine generated from LSEG data November 7 at
04:26 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.12          -1.17          Missed
 Jun. 30 2024      -1.29          -1.05          Beat
 Mar. 31 2024      -1.26          -1.33          Missed
 Dec. 31 2023      -1.27          -1.43          Missed